确定PLAC1作为清细胞脏细胞癌的预后生物标志物和分子标
Ying Kong1, Zongming Jia1, Yizhang Sun1
1Department of Urology, the First Affiliated Hospital of Soochow University, Suzhou 215000, China.
Cellular signalling
|January 15, 2025
概括
研究人员确定了胎盘蛋白1 (PLAC1) 作为清细胞脏细胞癌 (ccRCC) 的有前途标. 抑制PLAC1显示了治疗ccRCC的潜力,提供了新的治疗途径.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 遗传学 是一个遗传学.
背景情况:
- 清细胞细胞癌 (ccRCC) 由于有效治疗方法有限,存在重大临床挑战.
- 识别新的分子标对于推进ccRCC治疗至关重要.
研究的目的:
- 研究PLAC1在ccRCC发育和进展中的作用.
- 为了确定针对PLAC1进行ccRCC治疗的潜在治疗剂.
主要方法:
- 对PLAC1表达的TCGA数据库的分析.
- 西方涂抹和免疫光以验证PLAC1水平.
- 在体外实验中涉及PLAC1敲击的实验.
- 高通量虚拟选 (HTVS) 用于识别PLAC1抑制剂.
主要成果:
- 发现PLAC1在ccRCC组织中显著过度表达.
- 高PLAC1表达与患者预后不佳相关.
- 在体外抑制PLAC1抑制ccRCC细胞的增殖.
- AmB和Cana被确定为抑制剂,可降低PLAC1表达和ccRCC进展.
结论:
- PLAC1 作为 ccRCC 的潜在预后生物标志物.
- AmB和Cana通过通过PLAC1降低抑制ccRCC进展来证明其治疗潜力.
更多相关视频
相关概念视频
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
mTOR Signaling and Cancer Progression
3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.7K


